Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse

Antzeko izenburuak

• The prevalence of extramedullary acute myeloid leukemia detected by 18FDG-PET/CT: final results from the prospective PETAML trial
  nork: Friedrich Stölzel, et al.
  Argitaratua: (2020-06-01)
• Minimal residual disease-directed preemptive treatment with azacitidine in patients with NPM1-mutant acute myeloid leukemia and molecular relapse
  nork: Katja Sockel, et al.
  Argitaratua: (2011-10-01)
• Symptomatic central nervous system involvement in adult patients with acute myeloid leukemia
  nork: Alakel N, et al.
  Argitaratua: (2017-03-01)
• Mobilization of PML/RARα negative peripheral blood stem cells with a combination of G-CSF and CXCR4 blockade in relapsed acute promyelocytic leukemia pre-treated with arsenic trioxide
  nork: Friedrich Stölzel, et al.
  Argitaratua: (2010-01-01)
• Spatial heterogeneity and differential treatment response of acute myeloid leukemia and relapsed/refractory extramedullary disease after allogeneic hematopoietic cell transplantation
  nork: Desiree Kunadt, et al.
  Argitaratua: (2022-08-01)